FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 7, 2018 Category: Drugs & Pharmacology Source Type: news
Cipla gets USFDA approval for HIV drug
Citing IMS Health data, the company said Viread Tablets, 300mg, had US sales of approximately USD 725 million for the 12-month period ending November 2017. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 29, 2018 Category: Pharmaceuticals Source Type: news
HIV Prevention Trials Network (HPTN) announces initiation of HPTN 084
(FHI360) The HIV Prevention Trials Network (HPTN) today announced the initiation of HPTN 084, a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2017 Category: International Medicine & Public Health Source Type: news
Single-Pill HIV Regimen Scores in New Patients Single-Pill HIV Regimen Scores in New Patients
A new single-tablet regimen with boosted darunavir and tenofovir alafenamide works in virally suppressed HIV patients, AMBER trial results confirm, but when should it be tried in the treatment na ï ve?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
Tenofovir Prodrug Goes Head to Head Against Abacavir in HIV Tenofovir Prodrug Goes Head to Head Against Abacavir in HIV
A lot has been made of the better renal and bone safety with the tenofovir alafenamide prodrug than with the older formulation, but is it better than other antiretrovirals?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
Single-tablet Switch Option Effective in Virologically Suppressed HIV Single-tablet Switch Option Effective in Virologically Suppressed HIV
A new single-tablet regimen (STR) that includes the protease inhibitor (PI) darunavir, cobicistat, emtricitabine, and tenofovir alafenamide maintains viral suppression in adults infected with HIV-1, according to results from the EMERALD phase 3 noninferiority trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2017 Category: Pharmaceuticals Source Type: news
HIV prevention drug could save NHS £1 billion over 80 years
Conclusion
Evidence to support the use of Prep is building. Studies have shown that it is very effective at reducing the chances of becoming infected with HIV, for men at risk of infection through unprotected sex with men.
The question is more about the cost of treatment – and who should fund it – than whether it works.
NHS England previously went to court to say that it should not be responsible for funding Prep, as it is a preventive treatment, and therefore should come under health promotion budgets held by local authorities.
The High Court ruled that the NHS was able to fund the drug. NHS England has since said it ...
Source: NHS News Feed - October 19, 2017 Category: Consumer Health News Tags: Medication Source Type: news
Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens
EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2017 Category: Pharmaceuticals Source Type: news
Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1
A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
New Guidelines Issued on HIV Treatment During Pregnancy (FREE)
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Tenofovir-emtricitabine should not be a first treatment choice for women with HIV who are pregnant, according to new patient-centered … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 12, 2017 Category: Primary Care Source Type: news
Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women
Maraviroc-containing regimens appear to be safe and well tolerated, compared with tenofovir-emtricitabine (TDF-FTC), for preventing HIV infection in women, according to results from a phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Aurobindo Pharma gets USFDA nod for anti-HIV drug
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2017 Category: Pharmaceuticals Source Type: news
Mylan rolls out HIV treatment medicine in Canada
Mylan launched three generic medications to treat HIV in Canada.
The pharmaceutical company, which is based in the Netherlands but run out of its corporate offices in Canonsburg, said it had received Health Canada approval for these generic drugs:
emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada efavirenz/emtricitabin e/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla tenofovir disoproxil 300 mg, a generic alternative… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 10, 2017 Category: American Health Authors: Paul J. Gough Source Type: news
Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1
HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsid... Biopharmaceuticals, Generics, Product Launch Mylan, Truvada, Atripla, Viread (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 10, 2017 Category: Pharmaceuticals Source Type: news
